Biothera Inc.

Hibercell, Inc.

Nadine Ottoson

Nandita Bose

Jeremy Graff

Keith B Gorden

Xiaohong Qiu

Steven M Leonardo

Adria Bykowski Jonas

Ross Fulton

Takashi Kangas

Kathryn A Fraser

Anissa S H Chan

Anissa Sh Chan

Richard Huhn

Mark Uhlik

Jamie Lowe

Ben Harrison

Steven Leonardo

This disclosure provides, in one aspect, dosing strategies for soluble &#x3b2;-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble &#x3b2;-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Beta glucan immunopharmacodynamics

This disclosure relates to the combination of soluble &#x3b2;-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

&#x3b2;-glucan methods and compositions that affect the tumor microenvironment

The present invention relates to the combination of soluble &#x3b2;-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

Growing community of inventors

Lakeville, MN, United States of America

Nadine Ottoson